Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical …
News
Proteon Therapeutics Announces $22.0 Million Private Placement
Provides Sufficient Cash into Q4 2019 WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the …
CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine
International consortium of investors led by TVM Capital Life Science together with DPE Deutsche Private Equity, Careventures and CIC Capital CENTOGENE will continuously expand its R&D …
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney …
Attraktiv für Investoren! Individualisierte Medizin ist schon lange grundlegend für die erfolgreiche Behandlung von Patienten
Eine große Zahl von VC Investitionen im Life Science Bereich und deren Innovation sind implizit Investitionen in personalisierte Medizin oder Precision Medicine. Das können Beteiligungen an einer …
NOXXON PHARMA secures a private placement of 1 million Euro and additional financing of up to 10 million Euro through convertible notes with share subscription warrants attached to finance further clinical development of NOX-A12
Berlin, Germany, May 2, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, today …